Cure cash
Gilead uses grant program to place bets on best ways to clear HIV
With the goal now to clear rather than just suppress HIV, Gilead Sciences Inc. is using a $22 million grant program to back the scientific strategies it thinks are most likely to empty the HIV reservoir or produce better methods to measure it. High on its list is a toll-like receptor (TLR)-based “shock and kill” approach that could provide an alternative to Gilead’s own TLR7 agonist, GS-9620.
The program, whose 12 recipients were announced last month, will provide three years of no-strings-attached funding for academics, not-for-profits and community groups working on translational research and patient engagement related to HIV. ...
BCIQ Company Profiles